Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination
Authors:
- Matthaios SpeletasMSMatthaios Speletas
- Ioanna VoulgaridiIoanna Voulgaridi
- Zacharoula BogogiannidouZBZacharoula Bogogiannidou
- Styliani SarrouStyliani Sarrou
- Maria A. KyritsiMKMaria A. Kyritsi
- Aikaterini TheodoridouATAikaterini Theodoridou
- Katerina DadouliKDKaterina Dadouli
- Alexia MatziriAMAlexia Matziri
- Alexandros VontasAVAlexandros Vontas
- Dimitra PappaDPDimitra Pappa
- Adamos-Konstantinos KonstantinouAKAdamos-Konstantinos Konstantinou
- Christina TsigalouChristina Tsigalou
Open Access
Abstract
During the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From December 2020 to February 2023, a cohort study was conducted to estimate IgG and IgA immunogenicity and the dynamics of booster mono- and bivalent COVID-19 mRNA vaccines in 260 individuals (male/female: 114/146, median age: 68 years, interquartile range (IQR) = 31) who initially received either mRNA (218) or adenovirus-vector-based vaccines (42). Participants were followed until the 90th day after the third booster dose. Our cohort study indicated a beneficial effect of booster vaccination on the magnitude of IgG and IgA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We found that second and third booster doses were more protective than one against fatal disease (p = 0.031, OR 0.08). In conclusion, booster COVID-19 vaccination should be strongly recommended, especially to individuals at high risk for severe/fatal disease.Keywords
This publication has 30 references indexed in Scilit:
- Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, IsraelEmerging Infectious Diseases, 2022
- Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide SettingNew England Journal of Medicine, 2022
- Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination StrategiesVaccines, 2022
- Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccinesAnnals of Medicine, 2022
- Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysisScientific Reports, 2021
- Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 YearsJAMA, 2021
- COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter studyVaccine, 2021
- IgA Antibodies and IgA Deficiency in SARS-CoV-2 InfectionFrontiers in Cellular and Infection Microbiology, 2021
- Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 PatientsFrontiers in Immunology, 2021
- Monthly mobility inferred from isoscapes and laser ablation strontium isotope ratios in caprine tooth enamelScientific Reports, 2021